Iovance Biotherapeutics, Inc. Announces Closing of $57.5 Million Common Stock Public Offering Read more about Iovance Biotherapeutics, Inc. Announces Closing of $57.5 Million Common Stock Public Offering
Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Pricing of Its Public Offering of $50 Million of Common Stock
Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock Read more about Iovance Biotherapeutics, Inc. Announces Public Offering of Common Stock
Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer Read more about Iovance Biotherapeutics Announces Approval of First Clinical Trial Application by Competent Authority in Netherlands for a Phase 2 Trial of LN-145 for the Treatment of Patients with Cervical Cancer
Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center Read more about Iovance Biotherapeutics Enters into a Research Collaboration Focused on Hematologic Malignancies with The Ohio State University Comprehensive Cancer Center
Iovance Biotherapeutics to Present at Two Upcoming September Conferences Read more about Iovance Biotherapeutics to Present at Two Upcoming September Conferences
Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma Read more about Iovance Biotherapeutics Announces FDA Fast Track Designation for LN-144 for Treatment of Advanced Melanoma
Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications Read more about Iovance Biotherapeutics to Present Data at Upcoming ESMO 2017 Congress on Tumor-Infiltrating Lymphocyte Treatment for Lymphoma Indications
Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer Read more about Iovance Biotherapeutics Announces First Patient Dosed in C-145-04 Phase 2 Trial in Cervical Cancer
Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer Read more about Iovance Biotherapeutics Appoints Timothy Morris as Chief Financial Officer